Table 1.

Distribution of solicited and unsolicited adverse reactions and distribution of all assessed adverse events, grouped by blinded vaccination 1–3 and the optional 4th booster vaccination.

MSP1	Vaccination 1–3 (blinded)					Vaccination 4 (optional—open)
	SumayaVac-1			GLA-SE	0.9% NaCl	SumayaVac-1
	25 µg	50 µg	150 µg	5 µg	1 ml	25 µg	50 µg	150 µg
	N = 6	N = 12	N = 6	N = 4	N = 4	N = 5	N = 9	N = 4
Solicited systemic reaction	7 (2)	15 (7)	8 (3)	1 (1)	2 (1)	0 (0)	4 (1)	0 (0)
Immediate	1 (1)	2 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Delayed	6 (3)	13 (7)	7 (3)	1 (1)	2 (1)	0 (0)	4 (1)	0 (0)
Solicited local reaction	15 (5)	58 (12)	12 (4)	10 (4)	11 (3)	3 (3)	8 (5)	3 (3)
Immediate	5 (3)	4 (4)	1 (1)	1 (1)	3 (2)	0 (0)	0 (0)	1 (1)
Delayed	10 (3)	54 (12)	11 (4)	9 (4)	8 (4)	3 (3)	8 (5)	2 (2)
Unsolicited adverse events	63 (6)	147 (12)	55 (6)	43 (4)	33 (33)	19 (5)	30 (9)	15 (4)
All adverse events	85 (6)	220 (12)	75 (6)	54 (4)	46 (4)	22 (5)	42 (9)	18 (4)
Serious	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Permanent	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Mild/moderate/severe	73/12/0	209/10/1	72/3/0	51/3/0	46/0/0	17/5/0	38/4/0	17/0/1
Related/unrelated	54/31	160/60	55/20	33/21	35/11	15/7	33/9	14/4

Please observe different numbers of volunteers (N) in each group. The figures in cells (except bottom two lines) represent the number of events followed by the number of participants in brackets. The original clinical data underpinning this table are compiled in the Supplementary Table 3.

Solicited systemic reaction to the vaccine: solicited predefined systemic symptoms, at least possibly related.

Solicited local reaction to the vaccine: solicited predefined local symptoms, at least possibly related.

Immediate: occurring within 30 min.

Delayed: occurring between >30 min and 29 days.